問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Digestive System Department

Division of General Surgery

Division of Hematology & Oncology

Division of General Internal Medicine

China Medical University Hospital-Taipei (在職)

Digestive System Department

更新時間：2023-09-19

彭成元Peng, Cheng-Yuan
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 3 個月

  • D10456@mail.cmuh.org.tw

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

彭成元

List

116Cases

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

2018-08-28 - 2021-04-12

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects with Chronic Hepatitis B who are not currently on Treatment

  • Condition/Disease

    Viremic Chronic Hepatitis B

  • Test Drug

    GS-9688 Film-coated Tablets, 1.5mg

Participate Sites
5Sites

Terminated3Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2014-06-01 - 2016-04-30

Phase III

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, and GT6 Infection.

  • Condition/Disease

    Hepatitis C Virus

  • Test Drug

    MK-5172A

Participate Sites
3Sites

Terminated3Sites

2014-06-01 - 2016-04-30

Phase III

A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    MK-5172A

Participate Sites
3Sites

Terminated3Sites

2014-12-01 - 2017-06-30

Phase III

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT 1, GT 4 and GT 6 Infection in the Asia Pacific

  • Condition/Disease

    Chronic HCV GT 1, GT 4 and GT 6 Infection

  • Test Drug

    MK-5172A

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

2014-06-01 - 2016-05-31

Phase III

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin (P/R) with Chronic HCV GT1, GT4, GT5, and GT6 Infection

  • Condition/Disease

    Hepatitis C Virus

  • Test Drug

    MK-5172A

Participate Sites
3Sites

Terminated3Sites

2015-03-01 - 2019-06-30

Phase II/III

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial

  • Condition/Disease

    Chronic Hepatitis C

  • Test Drug

    MK-5172A

Participate Sites
10Sites

Terminated7Sites

Study ended1Sites

彭成元
China Medical University Hospital-Taipei

未分科

彭成元
China Medical University Hospital

Digestive System Department

2016-05-01 - 2020-04-30

Phase III

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Pembrolizumab (MK-3475) /KEYTRUDA

Participate Sites
7Sites

Terminated6Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

2011-08-30 - 2014-07-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Terminated17Sites

2020-02-01 - 2021-01-31

Phase I

A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)

  • Condition/Disease

    Chronic hepatitis B virus (CHB) infection

  • Test Drug

    EDP 514

Participate Sites
10Sites

Recruiting3Sites

Terminated7Sites

1 6 7 8 9 10 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB